ClinicalTrials.Veeva

Menu

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

E

Ethicon

Status

Enrolling

Conditions

Stress Urinary Incontinence

Treatments

Device: Intervention

Study type

Observational

Funder types

Industry

Identifiers

NCT04829357
ESC_2020_04

Details and patient eligibility

About

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Enrollment

195 estimated patients

Sex

Female

Ages

21+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:

  1. Stress urinary incontinence symptoms
  2. Diagnostic evaluation, a positive cough stress rest, to confirm diagnosis of stress urinary incontinence.
  3. Female subjects ≥ 21 years of age requiring treatment of SUI
  4. Desired surgical correction of stress urinary incontinence using synthetic sub-urethral vaginal slings
  5. Planned surgery for primary stress incontinence without concomitant prolapse surgery
  6. Patient able and willing to participate in follow-up
  7. Subject or authorized representative has signed the approved informed consent

Exclusion Criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study:

  1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires
  2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product
  3. History of previous synthetic, biologic or fascial sub-urethral sling
  4. Pregnancy or plans for future pregnancy
  5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice.
  6. Current genitourinary fistula or urethral diverticulum
  7. Reversible cause of incontinence (i.e. drug effect)
  8. Contraindication to surgery

Trial contacts and locations

4

Loading...

Central trial contact

Christine Romanowski

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems